Humanigen (formerly known as KaloBios) is repositioning and developing its proprietary monoclonal antibodies to meet some critical unmet needs in cancer science. The Company's focus is on making chimeric antigen receptor T-cell (CAR-T) therapy safer, better and more routine. Its lead asset lenzilumab is poised to begin testing for possible prophylaxis of neurotoxicity and cytokine release syndrome related to CAR-T treatment.